Search

Your search keyword '"Hatsuko Mikuni"' showing total 3 results
Start Over Author "Hatsuko Mikuni" Publisher elsevier
3 results on '"Hatsuko Mikuni"'

1. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD

Author

Hideki Inoue, Megumi Jinno, Shin Ohta, Yasunari Kishino, Tomoko Kawahara, Hatsuko Mikuni, Haruna Sato, Mayumi Yamamoto, Yoko Sato, Chisato Onitsuka, Yuiko Goto, Hitoshi Ikeda, Hiroki Sato, Tomoki Uno, Yoshitaka Uchida, Tomoyuki Kimura, Yoshito Miyata, Kuniaki Hirai, Tetsuya Homma, Yoshio Watanabe, Sojiro Kusumoto, Shintaro Suzuki, Issei Tokimatsu, Akihiko Tanaka, and Hironori Sagara

Subjects
COVID-19, SARS-CoV-2, COPD, Favipiravir, Systemic corticosteroid, Pneumonia, Diseases of the respiratory system, RC705-779
Abstract

Use of systemic corticosteroids for the treatment for coronavirus disease 2019 (COVID-19) among chronic obstructive pulmonary disease (COPD) patients is not well described. A 58-year-old man with fever and progressive dyspnea was admitted to the Showa University Hospital, and showed severe respiratory failure which needed mechanical ventilation. His chest computed tomography scanning showed emphysema and bilateral ground-glass opacity caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. He received 30 mg prednisolone for five days with antiviral drug of favipiravir, and was successfully extubated on day five. A SARS-CoV-2 polymerase chain reaction (PCR) test became negative on day 15. He was discharged on day 21. Serum IgM and IgG antibodies against SARS-CoV-2 converted to positive on day 7 and they kept positive on day 54 for both IgM and IgG. Combination treatment of short-course systemic corticosteroid and favipiravir might improve the prognosis for critically ill COVID-19 pneumonia with COPD without negative influence on viral clearance or antibody production.

Published
2020
Full Text
View/download PDF

3. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD

Author

Yoshio Watanabe, Shin Ohta, Tomoki Uno, Yoshito Miyata, Megumi Jinno, Hitoshi Ikeda, Haruna Sato, Yuiko Goto, Chisato Onitsuka, Issei Tokimatsu, Sojiro Kusumoto, Tomoyuki Kimura, Kuniaki Hirai, Tetsuya Homma, Yasunari Kishino, Tomoko Kawahara, Hiroki Sato, Shintaro Suzuki, Yoshitaka Uchida, Yoko Sato, Hatsuko Mikuni, Mayumi Yamamoto, Hideki Inoue, Hironori Sagara, and Akihiko Tanaka

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, medicine.drug_class, medicine.medical_treatment, Case Report, Favipiravir, Gastroenterology, MERS, middle east respiratory syndrome, 03 medical and health sciences, SRAS-CoV-2, severe acute respiratory syndrome coronavirus 2, 0302 clinical medicine, PCR, polymerase chain reaction, Internal medicine, medicine, COPD, SFTSV, severe fever with thrombocytopenia syndrome virus, ARDS, acute respiratory distress syndrome, COVID-19, coronavirus disease 2019, Mechanical ventilation, lcsh:RC705-779, Systemic corticosteroid, business.industry, SARS-CoV-2, GOLD, The Global Initiative for Chronic Obstructive Lung Disease, COVID-19, Pneumonia, lcsh:Diseases of the respiratory system, SpO2, peripheral capillary oxygen saturation, medicine.disease, ICU, intensive care unit, CT, computed tomography, respiratory tract diseases, 030228 respiratory system, Respiratory failure, COPD, chronic obstructive pulmonary disease, 030220 oncology & carcinogenesis, Prednisolone, CRP, C-reactive protein, Middle East respiratory syndrome, Corticosteroid, RSV, respiratory syncytial virus, business, medicine.drug, WBC, white blood cell
Abstract

Use of systemic corticosteroids for the treatment for coronavirus disease 2019 (COVID-19) among chronic obstructive pulmonary disease (COPD) patients is not well described. A 58-year-old man with fever and progressive dyspnea was admitted to the Showa University Hospital, and showed severe respiratory failure which needed mechanical ventilation. His chest computed tomography scanning showed emphysema and bilateral ground-glass opacity caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. He received 30 mg prednisolone for five days with antiviral drug of favipiravir, and was successfully extubated on day five. A SARS-CoV-2 polymerase chain reaction (PCR) test became negative on day 15. He was discharged on day 21. Serum IgM and IgG antibodies against SARS-CoV-2 converted to positive on day 7 and they kept positive on day 54 for both IgM and IgG. Combination treatment of short-course systemic corticosteroid and favipiravir might improve the prognosis for critically ill COVID-19 pneumonia with COPD without negative influence on viral clearance or antibody production.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results